268 related articles for article (PubMed ID: 9114046)
1. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.
Gervaix A; West D; Leoni LM; Richman DD; Wong-Staal F; Corbeil J
Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4653-8. PubMed ID: 9114046
[TBL] [Abstract][Full Text] [Related]
2. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L
J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865
[TBL] [Abstract][Full Text] [Related]
3. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.
Ochsenbauer-Jambor C; Jones J; Heil M; Zammit KP; Kutsch O
Biotechniques; 2006 Jan; 40(1):91-100. PubMed ID: 16454046
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
5. Testing anti-HIV activity of antiretroviral agents in vitro using flow cytometry analysis of CEM-GFP cells infected with transfection-derived HIV-1 NL4-3.
Frezza C; Grelli S; Federico M; Marino-Merlo F; Mastino A; Macchi B
J Med Virol; 2016 Jun; 88(6):979-86. PubMed ID: 26519867
[TBL] [Abstract][Full Text] [Related]
6. Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line.
Pirounaki M; Heyden NA; Arens M; Ratner L
J Virol Methods; 2000 Mar; 85(1-2):151-61. PubMed ID: 10716348
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
Mayers DL
Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
[TBL] [Abstract][Full Text] [Related]
9. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.
Walter H; Schmidt B; Korn K; Vandamme AM; Harrer T; Uberla K
J Clin Virol; 1999 Jun; 13(1-2):71-80. PubMed ID: 10405894
[TBL] [Abstract][Full Text] [Related]
10. An indicator cell assay for T-cell tropic, macrophage-tropic, and primary isolates of HIV-1 based on green fluorescent protein.
Dorsky DI; Harrington RD
J Acquir Immune Defic Syndr; 1999 Nov; 22(3):213-20. PubMed ID: 10770340
[TBL] [Abstract][Full Text] [Related]
11. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
[TBL] [Abstract][Full Text] [Related]
12. Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.
Chiba-Mizutani T; Miura H; Matsuda M; Matsuda Z; Yokomaku Y; Miyauchi K; Nishizawa M; Yamamoto N; Sugiura W
J Clin Microbiol; 2007 Feb; 45(2):477-87. PubMed ID: 17182760
[TBL] [Abstract][Full Text] [Related]
13. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
[TBL] [Abstract][Full Text] [Related]
14. Stavudine selectively induces apoptosis in HIV type 1-infected cells.
Hashimoto KI; Tsunoda R; Okamoto M; Shigeta S; Baba M
AIDS Res Hum Retroviruses; 1997 Jan; 13(2):193-9. PubMed ID: 9007205
[TBL] [Abstract][Full Text] [Related]
15. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Connell EV; Hsu MC; Richman DD
Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
[TBL] [Abstract][Full Text] [Related]
16. A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro.
Moussazadeh M; Hua J; Sidhu MK; Zhao XX; Fitzgibbon JE; Liao MJ; Rashidbaigi A
Antiviral Res; 1999 Jul; 42(3):177-87. PubMed ID: 10443530
[TBL] [Abstract][Full Text] [Related]
17. A novel dual luciferase assay for the simultaneous monitoring of HIV infection and cell viability.
Mitsuki YY; Yamamoto T; Mizukoshi F; Momota M; Terahara K; Yoshimura K; Harada S; Tsunetsugu-Yokota Y
J Virol Methods; 2016 May; 231():25-33. PubMed ID: 26898957
[TBL] [Abstract][Full Text] [Related]
18. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
Miyake H; Iizawa Y; Baba M
J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
[TBL] [Abstract][Full Text] [Related]
20. Detection of HIV-1 infection with a green fluorescent protein reporter system.
Dorsky DI; Wells M; Harrington RD
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(4):308-13. PubMed ID: 8948367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
